Download presentation
Presentation is loading. Please wait.
Published byAntonia Logan Modified over 7 years ago
3
30 years as a biotechnological company to research to develop to produce to commercialize Biotechnological process for HEALTH
6
strong bet in RESEARCH 19812012 Projects Patents Publicactions Implantation of new technologies
7
19811983 NO COMMERCIAL ACTIVITY
8
1981198319841991 1 COMMERCIAL PRODUCT Equipments, Diversification, R&D Contracts FINANCIAL CRASH OF THE MAIN SHAREHOLDER 1992 NO COMMERCIAL ACTIVITY
9
1981198319841991 1994 NEW STRATEG COMMERCIAL RANGE DEVELOPMENT ? CAPITAL 1 COMMERCIAL PRODUCT Equipments, Diversification, R&D Contracts NO COMMERCIAL ACTIVITY
10
19942011 COMMERCIAL ACTIVITY 40 Mill de Pts 5,1 Mill de € 100% PRIVATE
11
Private capital 100 %
12
Tools for reaching our objectives
13
Toos for reaching our objectives technologies know how human team
15
Human team 42 people universitary degree (biologists, veterinarian, biochemist) Technicians Assistants External Service Administration 20 12 5 1 4
17
Immunoassays PCR Mab development Protein expression systems Transcriptonic Phage-display thecnologies
18
Immunoassays PCR Mab development Protein expression systems Transcriptómic Phage-display
19
Immunoassayss based on the specific binding between antígen and antibody ELISAs Immunochromatografic test
21
Immunoassays PCR Mab development Protein expression systems Transcriptómic Phage-display
22
PCR techniques based on the replication of specific sequences of nucleic acids x2x2 x2x2 x2x2 x2x2 x2x2 x2x2 x2x2 x2x2 x2x2
25
PCR
26
Immunoassays PCR Mab development Protein expression systems Transcriptómic Phage-display
27
Monoclonal Antibodies Development Originate biological systems able to produce an antibody (immunoglobulin) specific for a single antigenic determinant TRADITIONAL METHODNEW TECHNOLOGY + development production PHAGE DISPLAY
28
Immunoassays PCR MAb development Proteins expression system Transcriptomic Phage-display
29
Proteins expression system Use of the cellular system to synthesize peptides or proteins of interest
30
Proteins expression system Use of the cellular system to synthesize peptides or proteins of interest
31
Proteins expression system PROCARIOTIC SYSTEM EUCARIOTIC SYSTEM
32
Immunoassays PCR MAb development Proteins expression system Transcriptomic Phage-display
33
Transcriptomic Evaluation of the expression level of particular genes by studding the mRNA present in the cells. Arrays Bioinformatics analysis
34
Immunoassays PCR MAb development Proteins expression system Transcriptomic Phage-display
35
Allows knowing and selecting sequences codifying for biologically “useful” peptides or proteins. Uses the ability of some phages to expose at their capside proteins or peptides codified by genes artificially inserted in their genome. PHAGE
36
Phage-display PHAGO A gene from a library of genes
37
Phage-display PHAGO each phage receives a different and unique gene Each phage will expose at its capside one kind of exogenous protein or peptide
38
PHAGE Phage-display In every phage, there is a coexistence between the gene and the protein codified by this gene.
39
PHAGE Phage-display If we are able to select the phages through the activity of the protein they express …. … we have selected the gene which codify for this protein!
40
know how
41
79 Publications 62 Patents 36 Proyects
42
Our OBJETIVE is still the same
44
OBJETIVE research development production commercialization Biotechnology procedures applied to HEALTH animal plants human food
45
OBJETIVE research development production commercialization Biotechnology procedures applied to HEALTH animal plants human food
46
R esearch + D evelopment R&D
47
DUAL Strategy SHORT-TERM Diagnostic Procedures Short periods for registration Using industrial structure = very quickly in the market COMMERCIAL ACTIVITY LONG-TERM Vaccines and therapeutics Long periods for registration Require a bigger industrial structure to be in the market. PATENTS LICENSE
48
R & D Short Term R&D, today on market Actual product catalogue:
49
Veterinarian diagnosis 8 animal species 61 pathologies 105 references R & D Short Term R&D, today on market Actual product catalogue:
50
R & D Short Term R&D, today on market Actual product catalogue:
51
R & D Short Term R&D, today on market Actual product catalogue: Plant diseases diagnosis Food safety Human diagnosis
52
R & D Short Term R&D, today on market Actual product catalogue:
53
R & D Short Term R&D, today on market Actual product catalogue: Technologies Elisas Inmunochromatografy PCRs
54
R & D LongTerm R&D, actual ID projects
55
R & D Long Term R&D: actual R&D projects We are a small company, but we have surrounded ourselves by great institutions in many of our projects: ID-DLO (NL) SVIV (DK) Inst. PASTEUR (FR) OXFORD Univ. (UK)
56
R & D Long Term R&D: actual R&D projects
57
R & D Long Term R&D: actual R&D projects VI Programa Marco Immune Response to respiratory virus infections and vaccination in elderly.
58
New tools and approaches to control Porcine Reproductive and Respiratory Syndrome in the EU and ASIA (PRSSCon)” Development of multivalent vaccines for BTV, EHDV and AHSV (ORVIVAC) R & D Long Term R&D: actual R&D projects VII Programa Marco Evaluating and controlling the risk of African Swine Fever in the EU (ASFRisk) Strategies for the eradication of Bovine Tuberculosis. (TB-Step)
59
R & D Long Term R&D: actual R&D projects
60
R & D Long Term R&D: actual R&D projects Research and Development of new technologies for therapeutic applications and diagnosis for Cancer. 2006-2010. Cenit porject
61
R & D Long Term R&D: actual R&D projects Biomarkers searching for colon, lung, ovary and melanoma cancers and development of tests for diagnosis/prognosis
62
R & D Long Term R&D: actual R&D projects Our partners in the project:
63
R & D Long Term R&D: actual R&D projects Technologies and phases of the project in which we participated: Levels of genic expression analysis for biomarkers selection Specific antibodies development to the selected biomarkers MONOCLONAL ANTIBODIES TRANSCRIPTONICS ASSAYS DEVELOPMENT Desing and completion of detection tests (ELISA DAS, IC)
64
M anufacturing & S ales M & S
65
manufacturing under rigorous QC rules and controls
66
M & S Facilities Reagents preparation 01
67
M & S Facilities Coating plates 02
68
M & S Facilities Coating plates 02
69
M & S Facilities Coating plates 02
70
M & S Facilities Coating plates 02
71
M & S Facilities Packaging and storage 03
72
M & S Facilities Packaging of kits 04
73
M & S Products distribution
74
M & S Products distribution Large distribution net world wide 3956 distributorspresents in countries
75
M & S Products distribution NARVAC 2 CL TSENG LIFE STAR MICRONIC AGROVET SCIENTIFIC LINE MEGAPHARMA TIN HANG
76
M & S Products distribution NOACK BIOGNOSIS PLATERO QEFII DIACHEL PRIONICS AGROLABO TRASCO INGENASA
78
still growing...
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.